Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.

ABSTRACT: Rifamycin antibiotics are a valuable class of antimicrobials for treating infections by mycobacteria and other persistent bacteria owing to their potent bactericidal activity against replicating and non-replicating pathogens. However, the clinical utility of rifamycins against Mycobacterium abscessus is seriously compromised by a novel resistance mechanism, namely, rifamycin inactivation by ADP-ribosylation. Using a structure-based approach, we rationally redesign rifamycins through strategic modification of the ansa-chain to block ADP-ribosylation while preserving on-target activity. Validated by a combination of biochemical, structural, and microbiological studies, the most potent analogs overcome ADP-ribosylation, restored their intrinsic low nanomolar activity and demonstrated signific

SUBMITTER: Lan T 

PROVIDER: S-EPMC9633546 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature